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PHIPing Out: A Genetic Basis for
Tumor Ulceration
Jack L. Arbiser1
Ulceration is a common negative prognostic marker of solid tumors including
melanoma. The signaling basis of ulceration is being elucidated. PHIP has been
found to be amplified in wild-type melanomas, resulting in Akt activation and
aerobic glycolysis (Warburg effect), associated with ulceration. The ulceration
phenotype likely represents the genotype of the reactive oxygen driven tumor, in
which reactive oxygen drives angiopoietin-2 production, tumor growth, and
invasion. This phenotype is amenable to pharmacologic intervention.
Journal of Investigative Dermatology (2014) 134, 600–602. doi:10.1038/jid.2013.443
Ulceration is a common phenomenon
in dermatology and an adverse prognos-
tic factor in melanoma. For many years,
ulceration has been described as ‘‘a
tumor outgrowing its blood supply’’.
However, if blood supply is insufficient,
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why is ulceration an adverse prognostic
factor? We have shown that the majority
of cutaneous ulcers are not due to insuf-
ficient vascularity, but due to excess
vascularity (Arbiser et al., 2003). High
levels of matrix metalloproteinases
and unstable vasculature result in a
‘‘hostile’’ environment for epitheliali-
zation, leading to ulceration (Munavalli
et al., 2003). Ultimately, the factors
that promote ulceration are not well
understood.
Kashani-Sabet et al. have now identi-
fied pleckstrin homology domain–
interacting protein (PHIP) copy number,
initially as the top-rated gene differen-
tially expressed between metastatic
melanoma and primary melanoma
(Bezrookove et al. 2014). In this study,
they characterized PHIP as being expres-
sed at high levels in ulcerated melano-
mas. Not only was it present, the investi-
gators also demonstrated functional
consequences of PHIP overexpression.
Inhibition of PHIP led to a decrease in
aerobic glycolysis (Warburg effect). The
Warburg effect is commonly associated
with defective glucose metabolism, with
glucose being metabolized to lactate
instead of full metabolism through to
respiration. Although the ineffective
metabolism of glucose is initially counter-
intuitive in terms of tumor growth, more
recent studies have established that tumor
cells gain certain survival advantages
in exchange for switching to aerobic
glycolysis, namely NF-kB activation
and the ability to survive under extreme
hypoxia (Govindarajan et al., 2007). The
authors demonstrated the downregulation
of biomarkers of the Warburg phenome-
non, including LDH5, HIF1a, and VEGF.
Although this study demonstrates
PHIP elegantly as a potential therapeutic
target, several questions can be asked
that might provide elaboration and
answers about the role of PHIP in mela-
noma. First, is amplification the sole
mechanism of increased PHIP expres-
sion? If this is the case, adjacent genes
might provide advantages to melanoma,
because coamplification might increase
the expression of PHIP and an addi-
tional gene in a single step. Second,
what are the signaling pathways down-
stream of PHIP amplification? Glycolysis
is associated in melanoma with the
reactive oxygen–driven phenotype, in
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which reactive oxygen drives NF-kB
and angiopoietin-2 (Fried and Arbiser,
2008). Angiopoietin-2 is highly asso-
ciated with ulceration, and it would be
of interest to determine whether PHIP
overexpression causes increased reac-
tive oxygen generation and angio-
poietin-2 expression (Lapidoth et al.,
2009). Notably, as with ulceration,
angiopoietin-2 is associated with poor
prognosis in solid tumors, including
melanoma, lymphoid malignancies, and
in sepsis (Tanaka et al., 1999; Helfrich
et al., 2009; Kranidioti et al., 2009). If this
is the case, PHIP-overexpressing mela-
nomas might be susceptible to reactive
oxygen inhibition. Finally, could PHIP
overexpression be a mechanism of resis-
tance to Braf inhibition, especially as
PHIP has been associated with insulin
growth factor receptor 1 (IGFR1) signaling
(Reuveni et al., 2013)?
So-called targeted therapies have
focused on either Braf inhibition alone
or combination treatment with MEK
inhibitors. Predictably, resistance has
arisen owing to failure to affect the
phosphoinositol-3 kinase/Akt/reactive
oxygen pathway. The findings of PHIP
amplification in ulcerative primary mel-
anoma should provide an impetus for
targeting non-MEK/Braf pathways in
melanoma, as this has been a relatively
overlooked signaling pathway and one
that is readily targeted (Figure 1). Com-
bination or sequential targeting of MEK/
Braf inhibitors plus phosphoinositol-3
kinase/Akt/reactive oxygen pathway
inhibitors could well result in improved
long-term survival and even the possi-
bility of cure.
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Figure 1. Convergence of pathways in melanoma leads to NF-jB activation and glycolysis. The major
pathways in melanoma, Braf mutation, Nras mutation, and PHIP mutation all potentially involve a
superoxide/Akt/NF-kB pathway (reactive oxygen–driven pathway) to result in glycolysis, NF-kB activation,
and ulceration through angiopoietin-2 expression.
Clinical Implications
 Ulceration is a known poor prognostic factor for melanoma.
We now are beginning to understand that ulceration is a phenotype of a
specific type of signal transduction abnormality, likely that of the reactive
oxygen–induced phenotype.
 This phenotype can be targeted with inhibitors of superoxide production
(Munson et al., 2012), and in fact has already been used in patients with
melanoma (Arbiser et al., 2012).
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Secrets of the Cutaneous Basement
Membrane
Sarolta Karpati1
The paper in this issue by Has and co-workers reports 15 non-Herlitz epidermo-
lysis bullosa patients with the same single amino-acid substitution in collagen XVII,
all of whom presented with clinical and pathological features resembling Kindler
syndrome. Here we consider why and how a hemidesmosomal pathology can
mimic a focal adhesion bond disease, both clinically and ultrastructurally.
Journal of Investigative Dermatology (2014) 134, 602–604. doi:10.1038/jid.2013.452
In this issue of JID, Cristina Has and an
international group of specialists on
epidermolysis bullosa (EB) report on a
substitution mutation of collagen XVII
that is associated with several un-
expected skin and mucosal features
that are ordinarily not observed in
patients with junctional EB other (non-
Herlitz-type junctional EB) disease. The
authors also find a clinical overlap with
another inherited EB, the Kindler syn-
drome. Furthermore, the clinical fea-
tures developed rather late, years and
even decades after birth in most of
the patients, indicating a long-lasting
mechanism of functional compensation
and slow progression of the inherited
basement membrane (BM) damage.
Structural stability and dynamics
of collagen XVII within the
hemidesmosomal anchoring complex
The collagen XVII (180 kDa) was identi-
fied within the cutaneous basement
membrane zone (BMZ) chronologically
as the second, and functionally as the
major, autoantigen of bullous pemphi-
goid (BP), and therefore it has also been
called BPAG2 (BP antigen 2) or BP180.
The final product is a trimer of three
180 kDa a1 XVII chains [a1(XVII)3], and
it anchors basal keratinocytes at the
hemidesmosomal plaque through the
lamina lucida to the lamina densa of
the BM. Its intracellular N-terminal
domain contributes to hemidesmosomal
plaque stability, and it interacts with the
plaque proteins plectin and BPAG1
(BP230) and also with the intracellular
tail of b4 integrin. The 120 kDa extra-
cellular, flexible, collagenous ectodo-
main of the molecule is part of the
anchoring filament and, while binding
to the a6 integrin and laminin 332,
crosses the lamina lucida of the BM
where it anchors the lamina densa. This
ectodomain contains 15 collagenous
subdomains separated by 16 non-col-
lagenous (NC) interruptions (Birk and
Bruckner, 2011).
The 120 kDa ectodomain is shed from
the 180 kDa transmembrane mole-
cule at the external surface of basal
keratinocytes within the NC16 domain
by metalloproteinases of the ADAM
(A Disintegrin And Metalloproteinase)
family, predominantly by the tumor
necrosis factor-converting enzyme
(TACE alias ADAM 17) or by ADAM 9
or ADAM 10. The shed ecto-collagen
XVII functions as a ‘‘mobile’’ compo-
nent of the extracellular matrix (ECM); it
is present not only in the lamina lucida
but also in the uppermost dermal con-
nective tissue. The ectodomain acquires
new epitopes through proteolytic clea-
vage, which identify and distinguish the
cleaved molecules from the uncleaved
180 kDa protein. There are also smaller
shed ectodomains (e.g., 95 kDa) with
distinct cleavage sites and neoepitopes.
Neoepitopes within the NC16A domain
are recognized preferentially in auto-
immune blistering diseases such as BP,
pemphigoid gestationis, and the linear
IgA dermatosis (Nishie et al., 2010).
Ectodomain shedding weakens basal
keratinocyte binding to the underlying
BM when the architectural stability of the
molecule is disrupted. Shedding may be
of physiological importance during the
differentiation of the basal keratinocytes,
as well as in their movement during
wound healing and tissue regeneration
(Hashmi and Marinkovich, 2011).
Cross-talk along the BMZ: the key role
of b-integrins in adhesome interactions
The bidirectional interaction between cells
and their environment is mediated predo-
minantly via integrins that accumulate in
adhesomes. There are collagen-, laminin-,
and leukocyte-binding integrins. The abil-
ity of integrins to be activated and to
initiate signaling pathways depends upon
the type of adhesion complexes that are
formed between cells and the ECM. Acti-
vated integrins become clustered and form
dynamic integrin adhesomes, which are
‘‘signaling points’’ (Schiller and Fa¨ssler,
2013). Proteins that bind the intra-
cellular domain of b-integrins are able to
activate these b-integrins and to increase
their adhesion to the ECM. b1 integrins,
the largest integrin subfamily, are usually
involved in cell migration, proliferation,
and differentiation, and they participate
in development, tissue homeostasis,
and tumor progression. Integrin-targeted
biological therapies can be very effective
tools for tumor suppression (Marelli et al.,
2013).
Recent studies have demonstrated
how in genetically engineered cells diff-
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